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Common variable immunodeficiency (CVID) is a heterogeneous disorder characterized by antibody deficiency, poor humoral response
to antigens, and recurrent infections. To investigate the molecular cause of CVID, we carried out exome sequence analysis of a family
diagnosed with CVID and identified a heterozygous frameshift mutation, c.2564delA (p.Lys855Serfs*7), in NFKB2 affecting the C termi-
nus of NF-kB2 (also known as p100/p52 or p100/p49). Subsequent screening of NFKB2 in 33 unrelated CVID-affected individuals un-
covered a second heterozygous nonsense mutation, c.2557C>T (p.Arg853*), in one simplex case. Affected individuals in both families
presented with an unusual combination of childhood-onset hypogammaglobulinemia with recurrent infections, autoimmune features,
and adrenal insufficiency. NF-kB2 is the principal protein involved in the noncanonical NF-kB pathway, is evolutionarily conserved, and
functions in peripheral lymphoid organ development, B cell development, and antibody production. In addition, Nfkb2mouse models
demonstrate a CVID-like phenotype with hypogammaglobulinemia and poor humoral response to antigens. Immunoblot analysis and
immunofluorescence microscopy of transformed B cells from affected individuals show that the NFKB2mutations affect phosphoryla-
tion and proteasomal processing of p100 and, ultimately, p52 nuclear translocation. These findings describe germline mutations in
NFKB2 and establish the noncanonical NF-kB signaling pathway as a genetic etiology for this primary immunodeficiency syndrome.Introduction
Common variable immunodeficiency (CVID [MIM
607594]), which occurs in approximately 1:10,000 to
1:50,000 people,1–3 is a clinically and genetically heteroge-
neous disorder characterized by hypogammaglobulinemia
with poor response to antigens. CVID is one of the most
common primary immune deficiencies, with affected
individuals frequently presenting with recurrent sinopul-
monary infections as well as immune dysregulatory or
autoimmune features. Approximately 10%–20% of cases
are familial.4,5 The genetic defects responsible for CVID
have been identified in less than 10%–15% of all cases4,6
and include mutations in CD197 (MIM 613493), MS4A18
(CD20 [MIM 613495]), CR29 (CD21 [MIM 614699]),
ICOS10 (MIM 607594), TNFRSF13C11 (BAFFR [MIM
613494]), TNFRSF13B12,13 (TACI [MIM 240500]),
PLCG214 (phospholipase Cg2 [MIM 614878]), CD8115
(MIM 613496), LRBA16 (MIM 614700), and PRKCD17 (pro-
tein kinase Cd [MIM 176977]). Causative variants in these
genes typically affect peripheral or terminal B cell develop-
ment, in contrast to more severe antibody deficiencies,
such as X-linked agammaglobulinemia (MIM 300755),
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gous and heterozygous variants in TNFRSF13B, 1%–2% of
individuals harbor variants in ICOS, and the remainder of
the genes contribute to <1% of cases. The functional
contribution of TNFRSF13B variants in the disease is less
clear, because some variants are present in CVID subjects,
normal controls, and healthy relatives.19,20 A genome-
wide association study of CVID identified SNP associations
as well as copy-number variants in several gene regions,21
providing additional evidence that both single-gene muta-
tions andmore complex genetic mechanisms contribute to
the pathogenesis of CVID. This genetic heterogeneity may
result in differences in the CVID phenotype, including age
of onset, susceptibility to infection, autoimmunity, and
malignancy. These differences highlight the importance
of identifying additional molecular causes to predict dis-
ease onset, enable improved disease screening, and provide
new targets for treatment.
The NF-kB signal transduction pathway is well known
for its role in inflammatory and immune responses and in-
cludes the structurally homologous transcription factors
NF-kB1 (p105/p50), NF-kB2 (p100/p52), RelA (p65), RelB,
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whereas the noncanonical pathway, which includes
NF-kB2, affects specific aspects of B cell maturation, pe-
ripheral lymphoid development, bone metabolism, and
thymic development.22–24 In the nonactivated, resting
state, NF-kB proteins are typically sequestered in the cyto-
plasm. Activation of either pathway results in proteasomal
processing and translocation to the nucleus, where NF-kB1
or NF-kB2 bind their gene targets (see Figure S1 available
online). As opposed to the broad function and numerous
ligands of the canonical (NF-kB1) pathway that lead to
the production of inflammatory cytokines, the noncanon-
ical (NF-kB2) pathway has functional specificity. The pri-
mary noncanonical NF-kB2 ligands include lymphotoxin
b, B cells activating factor (BAFF), CD40 ligand (CD40L),
and receptor activator of NF-kB ligand (RANKL). BAFF re-
ceptor (BAFFR) deficiency is associated with a form of
CVID. Somatic mutations that activate the noncanonical
pathway/NF-kB2 have been associated with B cell lym-
phomas and other hematogenous malignancies.25–27
Together, these findings suggest that mutant proteins in
the noncanonical pathway are excellent candidates for
CVID pathogenesis.
We studied an index family affected by autosomal-domi-
nant, early-onset hypogammaglobulinemia with variable
autoimmune features as well as adrenal insufficiency. By
using an exome-sequencing approach, we identified a het-
erozygous mutation in NFKB2 (MIM 164012), the gene
that encodes NF-kB2, that affects the C terminus of the
protein, which prompted screening for additional NFKB2
mutations in our CVID cohort. We identified a second
NFKB2 mutation, also affecting the C terminus of
NF-kB2, in an unrelated CVID-affected individual with
the same features of hypogammaglobulinemia, autoim-
munity, and adrenal insufficiency. The causal effect of
these mutations is supported by our functional analysis
and byNfkb2mousemodels with similar CVID-like pheno-
types. We demonstrate the effects that the mutations have
upon NF-kB2 nuclear translocation and highlight the
importance of the noncanonical pathway for the study
of CVID.Material and Methods
Subjects
Blood samples were obtained from individuals with CVID, healthy
family members, and healthy control subjects. Informed consent
was obtained from all individuals and the legal guardians of
minors participating in studies approved by the University of
Utah Institutional Review Board.Clinical Laboratory Studies
Determination of lymphocyte subpopulations and immunoglob-
ulin levels was carried out via standard laboratory techniques,
including flow cytometry and nephelometry. Toll-like receptor
(TLR) functional assays with ligands to TLR1–TLR8 were per-
formed on peripheral blood mononuclear cells with supernatant
measurement of interleukin-1b (IL-1b), tumor necrosis factor-The Americanalpha (TNF-a), and IL-6 production measured by Luminex multi-
analyte technology (ARUP Laboratories). Cortisol and adrenocorti-
cotropic hormone (ACTH) levels were measured by standard
assays for clinical analysis.
B Cell Immunophenotyping
Whole blood was stained with CD19 PE (Beckman Coulter,
#6603846), CD27 APC (BD Bioscience, #655019), CD45 PerCP
(BD Bioscience, #340334), and IgD FITC (Dako, #F0189) in BD
TruCOUNT tubes (BD Bioscience, #340334). The data were ac-
quired on a FACS Canto II flow cytometer and analyzed with
FACSDiva software (BD Bioscience).
Exome Capture and Sequencing
Exome capture was performed on 3 mg of DNA samples with Roche
Nimblegen SeqCap EZHuman Exome Library capture probes v.2.0,
44.1 Mb (A.II.1, P1, P2, and P3) or v.3, 65 Mb (P4) performed ac-
cording to themanufacturer’s instructions followed by sequencing
on the Illumina HiSeq 2000. Exome libraries from family A were
sequenced on the HiSeq 2000 in individual lanes with paired-
end v2.5 chemistry, and individual P4 was indexed and pooled
with a second exome and sequenced in one lane of the HiSeq
2000 via paired-end, v.3 sequencing chemistry. High Density Cy-
toscan SNP arrays (Affymetrix) were run on family A to detect large
structural changes. Fastq files from exome data were mapped and
aligned to the reference genome (Genome Reference Consortium
Human build 37 [GRCh37]) with Burrows-Wheeler Aligner
(BWA).28 Alignments were subsequently refined by local realign-
ment around indels, PCR duplicate removal, and recalibration of
base quality scores via the Genome Analysis Toolkit software
(GATK)29 and SAMTools.30 Variants were called and variant call
format (VCF) files were generated with SAMTools, and GATK was
used for variant annotation. The SNP and Variation Suite (SVS)
software (Golden Helix) was used to filter the data sets for family
A based on the assumption of a dominant inheritance pattern.
The genomic position corresponding to c.2564delA (chr10:
104,161,900) was Sanger sequenced in the mother (P1), father
(A.II.1), son (P3), maternal grandparents (A.I.1 and A.I.2), and un-
affected child (A.III.3) by means of the primers shown in Table S1.
VAAST Analysis
Exome data from the four individuals in family A (A.II.1, P1, P2,
and P3) and the affected individual from family B (P4) were
analyzed with a version of the Variant Annotation, Analysis and
Search Tool (VAAST),31 which annotates and prioritizes SNVs
and indels. A dominant inheritance model and an expected
disease frequency of 1:10,000 were assumed. Variant files from
all three affected individuals in family A (P1, P2, and P3) were in-
tersected, the father (A.II.1) was subtracted, and a union was per-
formed between this variant file and the variant file from the
affected individual in family B (P4). Genes were annotated and
ranked by VAAST, and false positives were removed with VarBin,
a tool that prioritizes variants based on a false variant likelihood
prediction (J.D. Durtschi and R.L. Margraf, personal communica-
tion).
Genetic Screening of NFKB2 in a Collection of CVID
Simplex Cases
Genetic screening of NFKB2 by long-range PCR and Illumina
sequencing of a collection of 33 simplex CVID-affected individ-
uals were performed as described in Durtschi and Margraf et al.32Journal of Human Genetics 93, 812–824, November 7, 2013 813
Two primer sets with a 50 Amino Modifier C6 block were used to
spanNFKB25 1,000 bp to reduce the potential for allelic dropout.
Primers were designed to amplify a 9,648 base pair amplicon and a
9,695 base pair amplicon (Table S1). CVID simplex samples were
equimolarly pooled in two different pools (one with 16 samples
and one with 17 samples) with 250 ng total DNA in each pool.
DNA from the unaffected father in family A (A.I.1) was used as a
reference and pooled to a total of 160 ng. The c.2557C>T variant
was Sanger sequenced with the primers shown in Table S1.Cell Culture
Peripheral blood mononuclear cells (PBMCs) and Epstein-Barr
virus (EBV)-transformed B cell lines were maintained in complete
medium with RPMI-1640 with 2 mM L-glutamine, 10% fetal
bovine serum, penicillin (100 U/ml), and streptomycin
(100 mg/ml) at 37C in a humidified environment with 5% CO2.Immunoblotting
EBV-B cell lines at 13 106 cells/ml were incubated with or without
human CD40L (2 mg/ml) (Cell Signaling) for 4 hr in complete
medium. Cell lysates were prepared in RIPA buffer with HALT pro-
tease inhibitor cocktail (Pierce) and benzonase (Sigma-Aldrich). A
NE-PER nuclear and cytoplasmic extraction kit (Thermo Scientific)
was used according to manufacturer’s instructions for isolation of
nuclear and cytoplasmic cell fractions. To ensure equal loading,
protein concentrations were assessed via Bradford protein assay
(Bio-Rad). For protein identification, the following antibodies
from Cell Signaling were used: NF-kB2 p100/p52 (#4882), phos-
pho-NF-kB2p100 serine 866/870 (#4810), RelB (#4992), and
IKKa (#2682). Anti-IKKa (phospho S176 þ S180) antibody
(Abcam, ab17943) was used. A histone deacetylase 1 antibody
(HDAC1, H-51) (Santa Cruz Biotechnology, sc-7872) was used as
a nuclear fraction loading control and a HRP-conjugated b-actin
antibody (Abcam, ab20272) as a cytoplasmic or whole-cell lysate
loading control.Immunocytochemistry and Laser-Scanning Confocal
Microscopy
EBV-B cells (1 3 106 cells/ml) were stimulated with CD40L at
2 mg/ml for 4 hr. Cells were fixed with 4% paraformaldehyde in
phosphate-buffered saline, permeabilized with 0.3% Triton
X-100, and blocked with 5% goat serum. Cells were immuno-
stained with human-specific anti-NF-kB2 p100/p52 IgG (Cell
Signaling, #3017). Biotin labeling was completed with Biotin-XX
goat anti-rabbit IgG (Life Technologies, #B2770), followed by incu-
bation with Streptavidin Alexa 488-conjugated streptavidin (Life
Technologies, #S32354). Slides were counterstained with To-Pro-
3, which stains the nucleus, andmounted with Prolong Gold anti-
fade reagent (Molecular Probes) prior to imaging. All images were
generated on anOlympus FV-1000-XY confocalmicroscope with a
603 oil immersion objective at 13 zoom with z spacing of 1 mm.
Identical gain settings were used for image recording for all sam-
ples. Olympus Fluoview 1000 v.3.0 software (Olympus) was used
for blinded scoring analysis of all images. Percent nuclear translo-
cation of p52 was quantified with immunofluorescence confocal
imaging of wild-type (WT) and mutant (CVID) cell lines by
observing colocalization of the signal from anti-NF-kB2 p100/
p52 IgG and To-Pro-3. A minimum of 300 cells per slide per cell
line were counted in the control and affected groups, with 3 to 6
microscopy field images obtained per cell line.814 The American Journal of Human Genetics 93, 812–824, NovembStatistical Analysis
p values for confocal imaging analysis were calculated by a
nonparametric Wilcoxon rank-sum (Mann-Whitney) test imple-
mented in the STATA statistical software package (Stata Corp. LP:
STATA Statistical Software: Release 11).Results
Exome Sequencing and Genetic Screening Identifies
Heterozygous NFKB2 Mutations in CVID-Affected
Individuals
We studied a family affected by an autosomal-dominant
form of childhood-onset CVID (family A; Figure 1). Clin-
ical findings are summarized in Table 1, and case report
and laboratory findings are summarized in Table 2.
Affected individuals were diagnosed with CVID based on
(1) the presence of markedly reduced levels of serum im-
munoglobulins, including low IgG levels, (2) poor
response to antigens, and (3) a lack of criteria for diagnosis
of other well-defined antibody deficiency syndromes.
Individual P1 (A.II.2) is the biological mother of P2
(A.III.1), P3 (A.III.2), and A.III.3. She was diagnosed at 30
years of age with hypogammaglobulinemia at the time
her son (P3) was diagnosed. She had a history of recurrent
upper respiratory infections since childhood, including
sinusitis and pneumonias. Individual P2 is a daughter of
P1, born to nonconsanguineous parents of European
descent, and is the full sibling of P3. She was evaluated at
6 years of age after the CVID diagnosis of P3. She had a
history of recurrent infections, includingmultiple episodes
of otitis media and asthma. She has had significant autoim-
mune features of alopecia areata, vitiligo, and trachyony-
chia (Figure S2). P2 had interim patchy hair growth after
initiation of hydrocortisone replacement for adrenal insuf-
ficiency,whichsuggests anautoimmunemechanismofhair
loss. Recent nail cultures demonstrated presence ofCandida
albicans. Individual P3was evaluated at 3.5 years of agewith
a history of recurrent infections, asthma, and profound
hypogammaglobulinemia (Table 1). He had approximately
six episodes of pneumonia (several requiring hospitaliza-
tion), recurrent otitis media, and asthma. After multiple
episodes of hypoglycemia, he was found to have low
ACTH and cortisol levels. After the administration of syn-
thetic ACTH, his cortisol level remained low, which was
consistent with central adrenal insufficiency at the hypo-
thalamic or pituitary level. P1 and P2 were subsequently
diagnosed with central adrenal insufficiency. Of note,
both P3 and his healthy father (A.II.1) have type I Chiari
malformations (MIM 118420). The maternal grandparents
(A.I.1 andA.I.2) donothaveahistoryof recurrent infections
and have normal immunoglobulin levels and lymphocyte
counts (not shown). The youngest sibling in this family
(A.III.3) has not had recurrent infections and had normal
immunoglobulin levels at 20 months of age.
The transmission pattern in family A suggested aMende-
lian mode of inheritance, for which exome sequencing iser 7, 2013
Figure 1. NFKB2 Mutations in CVID
(A) Pedigrees for two families affected by childhood-onset CVID
with adrenal insufficiency. Mutation status of NFKB2 c.2564 for
family A and NFKB2 c.2557 for family B are indicated beneath
symbols for each individual (others were unavailable for testing).
WT indicates wild-type.
(B) Sanger sequencing of two individuals in family A over the
c.2564 position in NFKB2. Upper panel shows wild-type c.2564
position and lower panel shows the c.2564delA variant. Arrow
points to c.2564delA variant.
(C) Sanger sequencing of two individuals in family B over the
c.2557 position in NFKB2. Upper panel shows wild-type c.2557
position and lower panel shows the c.2557C>T variant. Arrow
points to the c.2557C>T variant.
(D)Multiple sequence alignment of amino acid sequences in the C
terminus of NF-kB2. The conserved lysine that acts as an acceptor
for ubiquitin is underlined and highlighted in red. The two
conserved serines required for phosphorylation are underlined
and highlighted in yellow.
(E) Schematic of NF-kB2 with the Rel Homology Domain (RHD)
and Ankyrin Repeat Domain (ARD) indicated by red boxes. The
location of the conserved lysine (K) and two conserved serines
(Phos) is indicated at top. The wild-type amino acid sequence is
listed below the protein figure with the conserved lysine and ser-
ines marked with red and yellow boxes, respectively. The amino
acid sequence for affected individuals in family A is shown second.
The amino acid sequence of the affected individuals in family B is
shown third, and the amino acid sequence for the mouse Lym1
mutation is shown fourth.
The Americanideally suited.34,35 Exome sequencing and genomic SNP
array analysis, followed by heuristic filtering of four mem-
bers of family A (A.II.1, P1, P2, and P3), showed that all
three affected individuals have a heterozygous frameshift
deletion (c.2564delA [p.Lys855Serfs*7]; RefSeq accession
number NM_001077494.2) in NFKB2, on chromosome
10q24 (Figure 1 and Tables S2 and S3). There were no large
structural variants shared between the affected individuals
in family A involving this gene or any of the known CVID
causative genes (data not shown). Heuristic filtering was
performed as described in Table S4.
An additional 33 CVID-affected individuals were tested
for variants in the NFKB2 gene, and one person (P4;
Figure 1, family B, B.II.3) with mutation c.2557C>T
(p.Arg853*; RefSeq NM_001077494.2) was identified
(Table S5). Among these 33 CVID-affected individuals,
this was the only one with known central adrenal insuffi-
ciency. CVID-affected individual P4 is unrelated to family
A and is of northern European descent. He presented
with hypogammaglobulinemia and recurrent upper respi-
ratory infections including recurrent otitis media and
pneumonia (Tables 1 and 2). He developed alopecia totalis
at 10 years of age. Additional autoimmune features
included trachyonychia (twenty-nail dystrophy) and psor-
iasiform dermatitis of the upper extremities confirmed by
biopsy with presence of numerous, mainly small lympho-
cytes in the epidermis. He had a prolonged bout of chronic
aseptic meningitis with pleomorphic lymphocytic cerebral
spinal fluid at 16 years. He was later found to have central
adrenal insufficiency characterized by low ACTH, low
cortisol levels, intermittent hypoglycemia, and a failed
ACTH stimulation test. He tested negative for anti-adrenal
antibodies, which also supports a central underlying cause
of adrenal insufficiency. The aseptic meningitis improved
after initiation of glucocorticoid and mineralocorticoid
replacement for his adrenal insufficiency, although it is
not clear if the two diagnoses were related.
Both the c.2564delA and the c.2557C>T mutations are
heterozygous, suggesting an autosomal-dominant mode
of transmission in both families. The father (B.I.1) of P4
was unavailable for testing. Neither variant was found in
dbSNP, Human Gene Mutation Database (HGMD),36
1000 Genomes,37 the Exome Variant Server database, or
an internal database of 50 exomes unrelated to families A
and B sequenced on the Illumina HiSeq 2000 instrument
at ARUP Laboratories. Exome sequencing was then per-
formed on P4. VAAST31 analysis with the exome data
from family A alone demonstrated that NFKB2 ranked
fourth genome-wide and met the criterion for genome-
wide significance (p < 2.38 3 106) (Table S6). Addition
of the exome-sequencing data from P4 into the VAAST
analysis resulted in NFKB2 ranking highest, with genes
ranked 2 and 3 predicted to be false positives by VarBin (Ta-
ble S7). In total, four individuals affected with CVID and
central adrenal insufficiency from two families (Figure 1)
harbored heterozygous mutations in the same C-terminal
region of NFKB2. In addition, none of the affectedJournal of Human Genetics 93, 812–824, November 7, 2013 815
Table 1. Clinical Features of Affected Individuals with Mutations in NFKB2
Subject A.II.2 (P1) A.III.1 (P2) A.III.2 (P3) B.II.3 (P4)
Sex female female male male
Age at time of study 36 yr 13 yr 11 yr 24 yr
Age at onset of infections childhood 18 mo 2 yr <2 yr
Age at CVID diagnosis 30 yr 6 yr 3 yr 10 yr
Infections VRIs, pneumonias,
sinusitis
VRIs, otitis media VRIs, pneumonias, sinusitis,
otitis media
VRIs, pneumonias, sinusitis,
otitis media
recurrent herpes
labialis, giardia
recurrent herpes
labialis, giardia
recurrent herpes labialis
Autoimmune features none alopecia totalis,
trachyonychia, vitiligo
none alopecia totalis, trachyonychia,
psoriasiform dermatitis
Autoantibodies present none thyroid peroxidase Ab glutamate decarboxylase Ab thyroglobulin Ab, thyroid
peroxidase Ab, (negative adrenal Ab)
Central adrenal insufficiency
(ACTH deficiency)
þ þ þ þ
Additional findings asthma asthma asthma asthma
Bell’s palsy onychomycosis (Candida
albicans culture positive)
type I Chiari malformation,
otherwise normal brain MRI
interstitial lung disease with
bronchial wall thickening
type I Chiari malformation
developmental delay
aseptic meningitis
pyloric stenosis
Abbreviations: plus sign (þ), presence of; Ab, antibody, MRI, magnetic resonance imaging; VRIs, viral respiratory infections; yr, years.individuals harbored candidate causal variants in any of
the genes previously associated with CVID.
B Cell Immunophenotyping Demonstrates Reduced
Memory B Cells in the CVID-Affected Individuals
All individuals withNFKB2mutations had low serum levels
of IgA, IgG, and IgM (Table 2). In two of the four affected in-
dividuals, counts of CD19þ B cells were normal. B cell
counts were markedly reduced in P1. Switched-memory B
cells as defined by CD19þCD27þIgD were low in all
affected individuals tested, and marginal zone/non-
switched memory B cells as defined by CD19þCD27þIgDþ
(Table 2 and Figure 2) were low in all affected individuals.
Substitutions p.Lys855Serfs*7 and p.Arg853* Truncate
NF-kB2
Full-length NF-kB2 is sequestered in the cytoplasm as the
precursor p100 in a complex with RelB. Activation of
NF-kB2 signaling requires a kinase cascade resulting in
phosphorylation of p100 at two conserved C-terminal ser-
ines (Ser866, Ser870)38 by the IKKa kinase (Figure S1). This
is followed by ubiquitination of a conserved lysine
(Lys855), also located at the C terminus of p100.24 Ubiqui-
tination acts as a signal for proteasomal processing of the
p100 C terminus to generate p52, which, in its heterodi-
meric configuration with RelB, is then translocated into
the nucleus where the active complex acts as a transcrip-
tion factor.816 The American Journal of Human Genetics 93, 812–824, NovembIn CVID family A, the NFKB2 c.2564delA variant is a
frameshift deletion that changes the conserved Lys855 to
a serine and introduces a premature stop codon at amino
acid 861 (Figure 1). In family B, the NFKB2 c.2557C>T
mutation introduces a premature stop codon at amino
acid 853. We hypothesized that the location of the two
substitutions not only would truncate NF-kB2 but also
would prevent (1) phosphorylation at the critical serine
sites, (2) ubiquitination, and (3) subsequent proteasomal
processing into active p52. NF-kB2 is conserved through
zebrafish, and the human protein shares 92% identity at
the amino acid level with mouse NF-kB2. Murine
Nfkb2 knockouts and an Nfkb2 mutant, c.2854A>T
(Nfkb2Lym1/Lym1, nonsense mutation p.Tyr868*), have
been demonstrated to have a CVID-like phenotype.39–41
The heterozygous NFKB2mutations in the two CVID fam-
ilies result in a C-terminal amino acid substitution less
than 10 amino acids upstream from the murine Lym1
Nfkb2 mutation site. The Nfkb2Lym1/Lym1 mouse displays
decreased serum immunoglobulins similar to the pheno-
type in the two CVID kindreds (Table S8).
To test the effect of the two NFKB2mutations on protein
size and stability, we isolated extracts from EBV-B cells
derived from kindred controls (A.I.2 and A.II.1), an unre-
lated healthy pediatric control, and individuals with
c.2564delA (P1, P2, and P3) and c.2557C>T (P4). Detec-
tion of NF-kB2 by immunoblotting demonstrated that
the premature stop codon results in a truncated form ofer 7, 2013
Table 2. Laboratory Findings in Affected Subjects with Mutations in NFKB2
Subject A.II.2 (P1)a A.III.1 (P2)a A.III.2 (P3)a B.II.3 (P4)a
Lymphocyte Subsets
Total lymphocyte count
(lympocytes/ml)
2,300 5,100 5,780 3,000 (1,500–7,000)
CD3þ 2,189 (570–4,000) 4,207* (1,000–2,200) 5,374* (1,200–2,600) 2,739* (677–2,383)
CD4þ 1,512 (430–1,800) 3,181* (400–2,100) 3,409* (300–2,000) 2,062* (425–1,509)
CD8þ 672 (210–1,200) 872 (330–920) 1,849* (300–1,800) 628 (169–955)
CD16þCD56þ 47* (78–470) 770* (70–480) 462 (100–480) 71* (101–678)
CD19þ 65* (91–601) 333 (200–600) 244* (270–860) 262 (99–527)
CD27IgDþ naive B cells
(% of CD19þ)
24.4%* (48.4%–79.7%)b 89.5%* (51.3%–82.5%)b 92.2%* (51.3%–82.5%)b ND
CD27þIgDþ marginal
zone/nonswitched
memory B cells (% of CD19þ)
2.4%* (7.0%–23.8%)b 1.7%* (4.6%–18.2%)b 2.0%* (4.6%–18.2%)b 0.7%* (1.7%–29.3%)c
CD27þIgD switched
memory B cells (% of CD19þ)
6.7%* (8.3%–27.8%)b 5.0%* (8.7%–25.6%)b 3.1%* (8.7%–25.6%)b 1.9%* (2.3%–31.8%)c
Immunoglobulins
IgG 75* (639–1,349) 148* (633–1,280) 144* (441–1,135) 269* (768–1,632)
IgM 11* (56–352) 12* (48–207) 5* (47–200) 13* (60–263)
IgA <15* (70–312) 8* (33–202) 8* (22–159) 16* (68–378)
IgE ND <2 <2 0.2
Vaccine Responses
Tetanus IgG (IU/ml) ND ND 0.80* (R1.00)d,e 1.61 (>0.10)d,e
Diphtheria IgG (IU/ml) ND ND 0.05* (R1.00)d,e 0.20 (>0.10)d,e
Pneumococcal IgG (mg/ml) ND ND R1.5 in 1 of 14 serotypes*e no response; <1.5 in
all 14 serotypes*e
Toll-like Receptor Function
TLR 1-8 stimulation with
measurement of IL-1b, IL-6,
and TNF-a production
normal normal normal normal
T Cell Spectratyping
small monoclonal TCRg
monoclonal population
with polyclonal background
normal normal ND
Endocrine Studies
Cortisol (mg/dl) 1* (1–25) <1.0* (1–23) <1.1* (1–23) <1.1* (1–23)
ACTH (pg/ml) <5* (5–27) 2–4* (5–46) <2–2* (5–46) 1–2* (6–55)
Failed ACTH stimulation test ND ND þ þ
Antithyroid antibodies ND thyroid peroxidase
Ab 36.5* (0.0–3.9);d
thyroglobulin
Ab 6.5 (0.0–14.4)d
ND thyroid peroxidase
Ab 68.9* (0.0–2.0);d
thyroglobulin
Ab 14.3* (0.0–2.0)d
Antiadrenal antibodies ND ND ND negative
Other findings mild transaminitis
Asterisk (*) indicates abnormal value; Abbreviations are as follows: plus sign (þ), presence; Ab, antibody; ND, not determined; TCR, T cell receptor; TLR, toll-like
receptor.
aNormal values for age provided in parentheses.
bReference range obtained from Piatosa et al.33
cReference range obtained from Mayo Medical Laboratories.
dReference range obtained from ARUP Laboratories.
eObtained 1 month after immunization.
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Figure 2. B Cell Immunophenotyping
(A) Dot plots demonstrate gating for CD19þ B cells.
(B) CD19þ B cells were then analyzed for CD27 and IgD expression.
Affected individuals (P1, P2, P3) demonstrate reduced absolute numbers and percent of switched-memory B cells (CD19þCD27þIgD) as
well as marginal zone/nonswitched memory B cells (CD19þCD27þIgDþ) compared to a healthy control. In addition, P1 demonstrates
markedly reduced CD19þ B cell numbers.p100 at 94 kDa (Figures 3 and S3). Because the affected in-
dividuals are heterozygous for the respective mutations,
both wild-type and mutant p100 are present in cells
derived from the affected individuals.
To test whether the truncated p100 mutant protein can
be phosphorylated, we exposed cells to exogenous
CD40 ligand (CD40L), a noncanonical NF-kB pathway
agonist,42 and probed cell extracts with phospho-specific
NF-kB2 antibody. The truncation removes the conserved
phosphorylation sites required for activation of p100 to
p52. This was confirmed in the mutant cell lines by the
presence of phosphorylated signal on the full-length,
wild-type p100 protein but not the truncated protein, as
well as reduced p52 signal (Figures 3 and S3). Similar results
were seen in all cell lines (data not shown). Therefore, the
truncated p100 protein in the mutant cell lines cannot un-
dergo C-terminal phosphorylation and ubiquitination
required for proteosomal processing into p52.
NF-kB2 Substitutions Result in Reduced Nuclear
Translocation of p52
We further investigated the effects of protein mutation (or
truncation) on lymphocyte function by examining nuclear
translocation of p52 and RelB, because p52:RelB dimers are
the principal transcriptional activators of the noncanoni-
cal pathway. Mutant cell line immunoblots demonstrated
decreased nuclear translocation of p52 and RelB compared
to wild-type cell lines after upregulation of the noncanon-
ical pathway with CD40L (Figure 4A, left). In order to phos-
phorylate p100, IKKa (CHUK [MIM 600664]; IkB kinase a)
must first be phosphorylated by NIK (NF-kB-inducing818 The American Journal of Human Genetics 93, 812–824, Novembkinase) (Figure S1), raising the possibility that NF-kB2
phosphorylation and nuclear translocation defects could
result from an upstream abnormality in IKKa levels or
function. Immunoblotting of total IKKa levels in the cyto-
plasmic fractions did not show a difference between
mutant and wild-type cell lines (Figure 4A, middle). In
addition, immunoblotting of phosphorylated IKKa
showed that cytoplasmic phospho-IKKa levels in mutant
cells were increased compared to wild-type cells, confirm-
ing that protein levels in upstream signaling molecules
were not a limiting factor in reduced NF-kB2 translocation
(Figure 4A, right). To determine whether the increase in
phospho-IKKa protein levels in cells from CVID-affected
individuals originated at the level of transcription, we
performed transcriptome analyses of primary B cells stim-
ulated with CD40L and saw no difference in CHUK expres-
sion (data not shown). Phospho-IKKa activates NF-kB2 at
two C-terminal serine residues, both of which are missing
in the CVIDmutant proteins. This suggests that there is an
accumulation of cytoplasmic phospho-IKKa resulting
from a lack of NF-kB2 substrate rather than because of
compensatory feedback mechanisms.
The immunoblot observations were supported by im-
munofluorescence microscopy in EBV-B cells from
P3 (Figure 4B) and B cell lines derived from the three
other CVID individuals. The EBV-B cells derived from an
unaffected individual (WT; A.II.1) demonstrated increased
NF-kB2 signal (green) colocalizing with the nuclear stain
(To-Pro-3, blue) upon pathway stimulation by CD40L
compared to unstimulated cells. In the mutant cell
lines, there was a statistically significant reduceder 7, 2013
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Figure 3. NF-kB2 Substitutions Lead to Protein Truncation and
Phosphorylation Defects
(A) Immunoblot of wild-type and truncated mutant NF-kB2/p100
(arrows) from whole-cell lysates of EBV-B cells derived from unaf-
fected (pediatric control, lane 1; A.I.2, lane 2; and A.II.1, lane 3)
and affected (P2, lane 4; P3, lane 5; P4, lane 6) individuals are
shown.
(B) Top panel shows immunoblot of wild-type andmutant NF-kB2
(arrows) from whole-cell lysates of EBV-B cells derived from unaf-
fected (WT, A.II.1) and affected (CVID, P3) individuals. Cells were
either treated (þ) with CD40 ligand (CD40L) to stimulate the
NF-kB2 pathway or left untreated () to compare the levels of
phosphorylation in wild-type and mutant proteins. Bottom panel
shows the same whole-cell lysates probed with an antibody that
specifically recognizes the phosphorylated p100 protein (P-NF-
kB2). Immunoblotting of actin was used as a loading control. Ar-
rows point to full-length (top) and truncated (bottom) forms of
NF-kB2. Arrowheads denote signals for protein being probed.(p < 1.0 3 105), but not completely abolished, NF-kB2
signal colocalizing with nuclear signal upon CD40L stimu-
lation compared to three control cell lines, suggestive of a
functional haploinsufficiency resulting from the heterozy-
gous NFKB2 mutations. Taken together, these results
demonstrate that NF-kB2 nuclear translocation is reduced
in the CVID-affected individuals.
Genetic Screening of Adrenal Insufficiency
Notably, all CVID-affected individuals in this study have
central adrenal insufficiency, in which both ACTH and
cortisol levels are low. This condition was identified after
the diagnosis of CVID. Central adrenal insufficiency is an
unusual feature among individuals with CVID. Genes
associated with central or primary adrenal insufficiency,
including PROP1 (MIM 601538), POU1F1 (MIM
173110), TBX19 (MIM 604614), POMC (MIM 176830),
CRH (MIM 122560), HESX1 (MIM 601802), OTX2 (MIM
600037), LHX3 (MIM 600577), LHX4 (MIM 602146),
SOX3 (MIM 313430), CRHR1 (MIM 122561), CRHR2
(MIM 602034), NR0B1 (MIM 300473), and AIRE (MIM
607358), were analyzed in our cohort for potential causa-
tive variants. Variants in these genes were considered if
they met the following criteria: read depth > 8, minor
allele frequency (MAF) < 5% in the 1000 Genomes Proj-
ect database, location within 10 bp of an exon, and pres-The Americanence in affected individuals and absence in unaffected
individuals. No variants met these criteria in family A.
Exome sequencing data from individual P4 were analyzed
separately and two synonymous variants were found in
two different candidate genes (LHX3 and LHX4) for adre-
nal insufficiency (Table S9). Both LHX3 and LHX4 muta-
tions have been associated with a combined pituitary
hormone deficiency (MIM 221750 and 262700) involving
decreased levels in multiple hormones generated by the
pituitary gland as well as other syndromic features.43–45
This phenotype differs substantially from that of the
described CVID-affected individuals and is therefore un-
likely to be causing the central adrenal insufficiency
seen in P4.Discussion
In this study, we demonstrate that heterozygousmutations
in NFKB2 cause a unique form of early-onset CVID that
also presents with central adrenal insufficiency. Although
CVID diagnoses occurred at 3 years of age or later, all
affected individuals (P1, P2, P3, and P4) presented with
recurrent infections during early childhood, have reduced
serum immunoglobulin levels, and require immunoglob-
ulin replacement therapy to prevent infections. Two of
the four have significant autoimmune manifestations
involving skin, hair, and nails, and all four have ACTH
deficiency. The four individuals from two families harbor
two distinct substitutions in the C terminus of NF-kB2.
Both substitutions introduce a premature stop codon in
the region of the protein that is required for posttransla-
tional modifications, specifically phosphorylation and
ubiquitination, leading to proteasomal processing. In
both cases, this results in reduced protein activation and
nuclear translocation.
Tucker et al. reported the Nfkb2 Lym1 mouse model,
which was created by chemical mutagenesis in a forward
genetic screen resulting in the nonsense mutation
c.2854T>A (p.Tyr868*) located at the C terminus of the
protein in the same region as the described individuals’
mutations (Figure 1D and Table S8).40 The Nfkb2Lym1/þ
heterozygous mice demonstrated an intermediate pheno-
type compared to the homozygous mutant, including
slightly increased mortality compared to wild-type,
absence of some peripheral lymph nodes, intermediate
foci of lung and liver inflammatory infiltrates, and inter-
mediate splenic architecture disruption. Nfkb2Lym1/Lym1
homozygous mice demonstrated reduced fertility, absence
of all peripheral lymph nodes, 100%mortality at 250 days,
severe inflammatory lesions in the lung and liver that
worsened with age, and severely disorganized splenic
architecture (see Table S10 for further comparisons).
Although not reported in the heterozygous mutant mouse,
the homozygous mutant had normal early B cell develop-
ment in the bone marrow but decreased serum immuno-
globulin levels and reduced peripheral B cell development,Journal of Human Genetics 93, 812–824, November 7, 2013 819
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Figure 4. NF-kB2 Substitutions Affect
Nuclear Localization of p52
(A) Nuclear (left) and cytoplasmic (middle
and right) fractions of EBV-B cells derived
from unaffected (WT, A.II.1) and affected
(CVID, P2) individuals were subjected to
immunoblotting with NF-kB2, RelB,
HDAC1, IKKa, phospho-IKKa, and actin
antibodies with (þ) and without () induc-
tion with CD40 ligand (CD40L) for 4 hr.
HDAC1 and actin were used as loading
controls for the nuclear and cytoplasmic
fractions, respectively.
(B) EBV-B cells derived from unaffected
(WT, A.II.1) and affected (CVID, P3) indi-
viduals were stained with a monoclonal
antibody against NF-kB2/p52 (green) and
To-Pro-3 (blue) nuclear stain. Scale bars
represent 25 mM. Cells were either stimu-
lated with CD40 ligand for 4 hr (CD40L)
or not stimulated (NS). Inset box in the
merged CD40L images is zoomed in the
image directly below. Arrows highlight
WT cells with NF-kB2 nuclear colocaliza-
tion, compared to those with reduced
NF-kB2 nuclear colocalization in the
CVID cells.
(C) Percent nuclear translocation of p52
was quantified via immunofluorescence
confocal imaging of wild-type and mutant
EBV-B cell lines after CD40L stimulation
for 4 hr. A minimum of 300 cells per slide,
per cell line were counted in the control
(WT; pediatric control, A.I.2, and A.II.1)
and affected (CVID; P2, P3, and P4) groups.
Circles represent one microscopy field for each of three cell lines per group. n ¼ 14 fields per group. Box plot denotes quartiles including
median. Whiskers indicate min and max values. p value was calculated by a nonparametric Wilcoxon rank-sum test.similar to the CVID phenotype seen in the affected indi-
viduals from families A and B.
In our study, we show that B cell lines from individuals
with heterozygous NFKB2 mutations have defective pro-
cessing of p100 to p52, and p52 translocation to the
nucleus is reduced but not completely blocked upon stim-
ulation of the noncanonical pathway (Figure 3). Processing
of p52 in the heterozygous Nfkb2Lym1/þmouse had similar
defects, with reduced but not completely abrogated nu-
clear translocation (Table S10). This is in contrast to the
homozygousNfkb2Lym1/Lym1 mouse, which showed a com-
plete absence of p52 upon stimulation of the noncanoni-
cal pathway. The Nfkb2Lym1/þ mouse model is consistent
with our two CVID families, in which there appears to be
a functional haploinsufficiency as a result of the heterozy-
gous C-terminal NFKB2 mutations. Although we cannot
absolutely exclude the possibility that expressed, truncated
alleles inhibit the pathway, we believe that haploinsuffi-
ciency is the more likely mechanism. If the mutations in
the CVID individuals were acting in a dominant-negative
manner with respect to NF-kB2 nuclear translocation, we
would expect that no or very little p52 from the wild-
type copy of NF-kB2 would be translocated to the nucleus.
Toll-like receptor assays in the individuals were normal
compared to controls, suggesting normal canonical
NF-kB signaling. Finally, Liang et al. demonstrated that820 The American Journal of Human Genetics 93, 812–824, Novembcell lines withmutations in either of the critical C-terminal
serine phosphorylation sites result in blocked p100 pro-
cessing.46 Thus, we suspect that the leaky defect, in which
some p52 is translocated to the nucleus in the families with
heterozygous NFKB2 mutations, is a result of the presence
of the wild-type p100, albeit in lower amounts compared
to controls, which can be processed and ubiquitinated,
and ultimately be translocated to the nucleus for transcrip-
tional regulation. Our data suggest that CVID pathogenesis
in humans with heterozygous NFKB2 mutations results
from haploinsufficiency restricted to the noncanonical
NF-kB pathway.
There are enough similarities to suggest that the Lym1
mouse provides an excellent model system for further
study of the relationship between NFKB2 and CVID. The
B cell maturational defects in the described individuals
provide additional evidence to support the causality of
the two NFKB2 mutations in our families. Mouse model
knockouts and mutants in the noncanonical NF-kB
pathway, including the Nfkb2 knockout mouse (Table
S8),39,40 have aberrant splenic and lymph node architec-
ture affecting germinal centers, which are critical for B
cell differentiation, as well as reduced antigen-specific anti-
body responses. Individuals with CVID may have normal
total B cell numbers, but the memory, class-switched,
and marginal zone B cells are often reduced in those wither 7, 2013
increased complications of the disease, which are indica-
tive of defects in peripheral and late B cell differentia-
tion.47,48 All four of the CVID-affected individuals reported
here have reduced antibody levels, poor response to immu-
nizations, and reduced memory and marginal zone B cells.
The effects of NF-kB2 are not limited to lymphoid organ
development and B cell maturation. The biological roles of
the pathway include thymic development49 and T cell
differentiation.24 The relationship of the noncanonical
NF-kB signaling pathway to thymic development and
autoimmune regulator (AIRE) expression has important
implications for central tolerance50,51 and can provide a
mechanism for development of autoimmunity in CVID.
AIRE is a transcription factor required for expression of
self-tissue antigens in the thymus, which removes autor-
eactive Tcells, ensuring an immune competent Tcell reper-
toire that is also self-tolerant. Reduced AIRE expression can
cause self-reactive T cells to enter the circulation. This
results in autoimmune-polyendocrinopathy-candidiasis-
ectodermal dystrophy (APECED or APS-1 [MIM
240300]),52 a syndromewith clinical heterogeneity charac-
terized by mucocutaneous candidal infections as well as
autoimmune organ disease, particularly involving the
endocrine glands. The candidal infections may in part be
due to autoantibodies against cytokines that are important
for the immune response against Candida,53,54 and the nail
dystrophy and alopecia seen in many of these individuals
are additional autoimmune findings. The Lym1 mouse
demonstrates reduced thymocyte AIRE expression.40 P2
has nail dystrophy, candidal nail infection, alopecia, and
central adrenal insufficiency, bearing very striking similar-
ities to APECED. P4 has nail dystrophy, alopecia, and cen-
tral adrenal insufficiency. These observations may provide
future directions for studying the autoimmunity seen in
the 20% of CVID individuals with autoimmune fea-
tures.55,56 Interestingly, none of our described CVID indi-
viduals has demonstrated autoimmune blood cytopenias,
which is one of the more common autoimmune findings
in CVID. Thus, specific gene mutations in CVID-affected
individuals may have specific phenotypic consequences,
and the mutations in NFKB2 may not result in autoim-
mune cytopenias, but may result in other autoimmune
sequelae. By extension, mutations in other genes, known
or yet to be identified as CVID causative, may have other
autoimmune sequelae such as cytopenias, and remain to
be investigated in further molecular detail.
A unique feature in our CVID cohort is the presence of
central adrenal insufficiency. Although rare, individuals
with hypogammaglobulinemia or CVID as well as ACTH
deficiency have been reportedwithout a known genetic eti-
ology.57–59 In addition,NFKBIA (NF-kB inhibitor IkBa [MIM
164008]) is a critical gene in the canonical NF-kB pathway,
with hypermorphic mutations known to cause autosomal-
dominant ectodermal dysplasia with immunodeficiency
(EDA-ID [MIM 612132]). A recent study described an
individual with a heterozygous NFKBIA mutation who, in
addition to the standard EDA-ID phenotype, also had a pol-The Americanyendocrinopathy with hypothyroidism and hypopituita-
rism.60 Adrenal insufficiency, whether central or primary,
can result from congenital, autoimmune, infectious, or
trauma-related causes. Adrenal function has not been
assessed in the Lym1 or Nfkb2 knockout mouse models.
The cause of the ACTH deficiency in the CVID-affected in-
dividuals reported here is unknown, but known genetic
causes were ruled out through filtering of shared variants
as well as screening of known genes associatedwith adrenal
insufficiency. This suggests that the NFKB2 variants are
causative for both the CVID and the central adrenal insuffi-
ciency (resulting from ACTH deficiency) phenotypes. The
link between the noncanonical NF-kB pathway and adrenal
or pituitary development and function has not previously
been described but should be further investigated inmouse
models. Based on what is known in APECED and Nfkb2
mouse models, we speculate that alterations in thymic
AIRE expression may result in aberrant T cell-mediated
self-tolerance of endocrine-related organs.
Adrenal insufficiency can cause severe hypoglycemia,
seizures, electrolyte imbalances, and nonspecific symp-
toms such as anorexia, nausea, vomiting, abdominal
pain, and weakness. The signs and symptoms of adrenal
insufficiency may become apparent only during times of
stress or illness. P4 had a prolonged bout of presumed
aseptic meningitis with nausea and vomiting, which in
part seemed to be corrected by addressing the adrenal
deficiency through steroid supplementation. P3 developed
hypoglycemia after an infection. In individuals with CVID,
we suggest that clinicians have a high clinical suspicion
and low screening threshold for adrenal insufficiency to
reduce morbidity and mortality associated with this easily
treated condition.
The genetic etiology of 85%–90% of CVID cases remains
unknown. Here we report four individuals with highly
penetrant NFKB2 variants in a collection of 37 CVID-
affected individuals, making this gene an excellent
candidate for diagnostic testing. The mainstay of CVID
treatment is lifelong immune globulin replacement, but
immune globulin does not treat the autoimmune features
of the disease. With a better understanding of the molecu-
lar pathogenesis of CVID, drugs targeting specific path-
ways can potentially be developed to allow for immune
reconstitution, addressing both the immune deficient as
well as autoimmune components seen in affected individ-
uals. In conclusion, our findings identify aberrant NF-kB2
function as a cause of CVID with adrenal insufficiency
and describe two unique germline human mutations in
NFKB2. Further studies of the NF-kB2 signaling pathway
will increase our understanding of the genetic and molec-
ular mechanisms underlying CVID pathogenesis that
could eventually lead to improved therapeutics.Supplemental Data
Supplemental Data include three figures and ten tables and can be
found with this article online at http://www.cell.com/AJHG/.Journal of Human Genetics 93, 812–824, November 7, 2013 821
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